Lymphact Overview

  • Founded
  • 2013
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A

Lymphact General Information


Provider of personalized medical treatments designed to focus on the treatment of cancer. The company's offers treatments through a technology platform that can generate autologous and allogeneic cellular immune therapies to target not only cancer and virus-infected cells, but also chemotherapy-resistant cancer stem cells and viral reservoirs for clinical applications, thereby enabling patients to get rid of chronic viral diseases quickly and painlessly.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Delivery
Primary Office
  • Zona Industrial De Cantanhede
  • Coimbra, 3060-197
  • Portugal
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Lymphact Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 30-May-2018 000.00 Completed Startup
3. Accelerator/Incubator 000.00 Completed Startup
2. Accelerator/Incubator 14-Sep-2013 $57.9K Completed Startup
1. Seed Round 01-May-2013 $57.9K $57.9K Completed Startup
To view Lymphact’s complete valuation and funding history, request access »

Lymphact Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Biocant Park Accelerator/Incubator Minority 000 0000 000000 0
Bynd Venture Capital Venture Capital Minority 000 0000 000000 0
Lisbon Challenge Accelerator/Incubator Minority 000 0000 000000 0
PME Investimentos Investment Bank Minority 000 0000 000000 0
Portugal Ventures Venture Capital Minority 000 0000 000000 0
To view Lymphact’s complete investors history, request access »